Document Detail


Staphylococcal skin infections in children: rational drug therapy recommendations.
MedLine Citation:
PMID:  15871629     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Staphylococcus aureus remains one of the most common and troublesome of bacteria causing disease in humans, despite the development of effective antibacterials and improvement in hygiene. The organism is responsible for over 70% of all skin and soft tissue infections in children and accounts for up to one-fifth of all visits to pediatric clinics. Skin and soft tissue infections that are predominantly caused by S. aureus include bullous and non-bullous impetigo, folliculitis, furunculosis, carbunculosis, cellulitis, surgical and traumatic wound infections, mastitis, and neonatal omphalitis. Other skin and soft tissue infections may also be caused by S. aureus but are often polymicrobial in origin and require special consideration. These include burns, decubitus ulcers (particularly in the perianal region), puncture wounds of the foot, as well as human and mammalian bites. Treatment of staphylococcal skin infections varies from topical antiseptics to prolonged intravenous antibacterials, depending on severity of the lesions and the health of the child. The treatment of choice for oral antibacterials remains the penicillinase-resistant penicillins such as flucloxacillin. Cefalexin and erythromycin are suitable cost-effective alternatives with broader cover, although care must be taken with the use of macrolides because of development of resistance to multiple families of antibacterials, particularly the lincosamides. Other cephalosporins such as cefadroxil and cefprozil are also effective, can be given once daily and have a better tolerability profile -- while azithromycin has a further advantage of a 3-day course. However, all of these agents are more expensive. Although the antibacterials have been given for 10 days in most clinical trials, there is no evidence that this duration is more effective than a 7-day course. In children requiring intravenous therapy, ceftriaxone has a major advantage over other antibacterials such as sulbactam/ampicillin and cefuroxime in that it can be given once daily and may, therefore, be suitable for outpatient treatment of moderate-to-severe skin infections. Newer-generation cephalosporins and loracarbef are also effective and have a broader spectrum of activity, but do not offer any added benefit and are significantly more expensive. Skin and soft tissue infections due to methicillin-resistant S. aureus (MRSA) are still relatively uncommon in children. Well children with community-acquired MRSA infections can be treated with clindamycin or trimethoprim-sulfamethoxazole (cotrimoxazole), but must be observed closely for potentially severe adverse effects. In severe infections, vancomycin remains the treatment of choice, while intravenous teicoplanin and clindamycin are suitable alternatives. Linezolid and quinupristin/dalfopristin are currently showing great promise for the treatment of multi-resistant Gram-positive infections. While the choice of antibacterial is important, supportive management, including removal of any infected foreign bodies, surgical drainage of walled-off lesions, and regular wound cleaning, play a vital role in ensuring cure.
Authors:
Shamez Ladhani; Mehdi Garbash
Related Documents :
3969409 - Dermodress: a new, temporary skin substitute for extensive deep burn coverage.
11958239 - Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the...
11297789 - The defense response elicited by the pathogen rhizoctonia solani is suppressed by colon...
25408299 - Non-invasive model of neuropathogenic escherichia coli infection in the neonatal rat.
8586839 - Rapid detection of meningococci from petechiae in acute meningococcal infection.
16218899 - Bacterial diseases of the skin.
24094379 - Overview of severe clostridium difficile infection.
1803499 - Cutaneous herpes simplex infection.
23984639 - The mirna world of polyomaviruses.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Paediatric drugs     Volume:  7     ISSN:  1174-5878     ISO Abbreviation:  Paediatr Drugs     Publication Date:  2005  
Date Detail:
Created Date:  2005-05-05     Completed Date:  2006-04-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100883685     Medline TA:  Paediatr Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  77-102     Citation Subset:  IM    
Affiliation:
Department of Paediatrics, Newham General Hospital, London, UK. DrShamez@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / therapeutic use
Child
Humans
Meta-Analysis as Topic
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Staphylococcal Skin Infections / diagnosis*,  drug therapy*
Staphylococcus aureus / drug effects,  growth & development
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and manageme...
Next Document:  Neonatal chlamydial infections: prevention and treatment.